masthead abstract

About Our AML Clinical Trial

The AML Clinical Trial is investigating the use of 131I apamistamab (Iomab-B) in patients age 55+ with active, relapsed or refractory Acute Myeloid Leukemia (AML), to enable bone marrow transplant (BMT).

Many AML patients today are not eligible for potentially curative bone marrow transplant because of their health status or they have active disease and are unable to get into remission with chemotherapy.  The SIERRA clinical trial for Acute Myeloid Leukemia may be an option for you. The trial does not require a patient to be in remission to potentially get a bone marrow transplant.

Edward Agura, MD, Texas Oncology – Baylor Charles A. Sammons Cancer Center Blood and Marrow Transplant, discusses the phase 3 SIERRA trial.

Study Design

The study design of the AML Clinical Trial

Study Locations

The SIERRA clinical trial Phase 3 Trial is now enrolling and being conducted at 22 major cancer centers in the United States and Canada:

Contact a SIERRA Clinical Trial Location

Download our SIERRA study summary to facilitate a discussion with your doctor about participating in the SIERRA AML clinical trial